<DOC>
	<DOCNO>NCT02763007</DOCNO>
	<brief_summary>Double blind , three arm , comparative intervention trial 24 week ( PEAK study ) open label extension trial 28 week follow 2 year observational study .</brief_summary>
	<brief_title>An Extension Study PEAK Trial</brief_title>
	<detailed_description>PEAK trial undergoing ( Multicenter , randomize , double blind , three-arm parallel group study evaluate efficacy safety Alogliptin Pioglitazone combination therapy glucose control type 2 diabetes subject inadequate control Metformin monotherapy Korea , Takeda No . ALO-IIT-012 ) . Duration combination treatment 24 week PEAK trial . Long-term efficacy safety alogliptin + pioglitazone + metformin combination therapy define Korea yet . Thus , extension PEAK trial longer treatment upto 1 year plan . PEAK trial follow another 28 week open-label treatment drug initial randomization ( total duration treatment randomize 52 week ) , follow 2 year observation . During observation period , antidiabetic medication added/changed HbA1c subject target 7 % clinician 's clinical decision . After 3 year initial randomization , durability glucose control assess 3 treatment group .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Completed `` ALOIIT012 ( PEAK study ) '' , without major protocol deviation . Male , female , 19 year 75 year . Female childbearing potential negative urine pregnancy test result study start willing continue practice appropriate birth control entire duration study Subjects complete PEAK include within 30 day End Of Study Subjects complete PEAK include treatment randomize even 30 day End Of Study . eGFR ( Epidermal growth factor receptor ) &lt; 50mL/min AST ( aspartate aminotransferase ) /ALT ( alanine aminotransaminase ) &gt; 2.5 upper limit normal Pregnant lactate woman Subject investigator deems inappropriate participate study Patients history bladder cancer patient active bladder cancer Patients uninvestigated macroscopic hematuria Patients cardiac failure history cardiac failure ( New York Heart Association [ NYHA ] Stages 3 4 ) Patients genetic problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption , since study drug contains lactose</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>